Trials / Completed
CompletedNCT03181113
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 473 (actual)
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon Alfa-2B | pre-received standard peginterferon alfa-2b therapy |
| DRUG | Peginterferon Alfa-2A | pre-received standard peginterferon alfa-2a therapy |
Timeline
- Start date
- 2016-05-18
- Primary completion
- 2020-09-21
- Completion
- 2020-09-21
- First posted
- 2017-06-08
- Last updated
- 2021-04-13
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03181113. Inclusion in this directory is not an endorsement.